When the rare stops being invisible: The Systemic Challenge of Rare Diseases

Why rare diseases have become a decisive test for equity, sustainability, and healthcare innovation.

In the vast ecosystem of global health, the word “rare” often carries the weight of isolation and neglect. However, when analyzing the data, rarity reveals itself as a mass phenomenon. It is estimated that 300 million people worldwide live with one of the more than 7,000 identified rare diseases. If these individuals formed a nation, they would be the third most populous country on the planet, only behind China and India. Given such magnitude, silence is not just an absence of sound but a barrier that limits timely access to diagnosis and treatment.

On this Rare Disease Day, visibility cannot remain mere rhetoric: it must translate into public policy, innovation, and real access. Transforming this scenario depends on an unnegotiable tripod: cutting-edge science, strategic visibility, and strengthened advocacy led by patient associations. Without the articulation of these pillars, innovation risks being confined to the laboratory, never effectively reaching those who need it.

The impact of a rare disease is multidimensional and often devastating for the family core. The journey is usually marked by the so-called “diagnostic odyssey”: on average, a patient takes between five and seven years to obtain a clinical confirmation after consulting about eight different specialists (RARE Diseases International, 2024). This delay is not harmless: it allows the progression of irreversible damage and generates profound wear: in the patient’s health, the emotional and economic balance of the family, and the healthcare system.

The socioeconomic and family impact is equally significant. A study by the EveryLife Foundation estimated that the total cost of rare diseases in the United States reached nearly one trillion dollars in a single year, considering both direct costs and productivity loss. This figure illustrates the magnitude of the economic challenge that rare diseases pose to any healthcare system. In contexts with more limited social protection networks, the burden can be even more severe. It is estimated that around 65% of caregivers, mostly women, must abandon their professional careers to fully dedicate themselves to patient care. This reality drags entire families into cycles of chronic financial vulnerability and productive exclusion.

Moreover, mental health is a critical factor. The emotional burden of living with a disease for which about 95% of cases still lack an FDA or EMA-approved treatment (Global Genes, 2024) is considerable. Prolonged uncertainty translates into significantly higher rates of anxiety and depression than those observed in people with prevalent chronic diseases. Those living with a rare disease face a double burden: that of the pathology itself and that of social misunderstanding.

Historically, patient associations were perceived mainly as emotional support networks. Today, they have consolidated as key actors in political and scientific transformation. Contemporary advocacy is not limited to demanding answers: it participates in building solutions. The role of these organizations is fundamental to facilitating access to innovative therapies, such as gene and cell therapies, which require a profound reconfiguration of healthcare systems.

These associations operate in areas where the state and market often do not reach. Regulatory acceleration remains a pending challenge in many countries. Organizations like EURORDIS in Europe, NORD in the United States, and Casa Hunter in Brazil have played a decisive role in positioning before agencies such as ANVISA, the FDA, and the EMA the adoption of more flexible evaluation frameworks that incorporate real-world evidence (RWE). This approach is key when traditional clinical trials are limited by the small number of patients.

Another structural challenge is the lack of patient data and registries. In low-prevalence diseases, information becomes the most strategic asset. In this context, associations promote and organize registries that allow understanding the natural history of the disease, facilitate the development of clinical trials in historically underrepresented populations, and create more favorable conditions for investment in research and development. This not only expands research activity but also promotes greater inclusion and diversity in the generation of available evidence.

However, the greatest challenge remains the sustainability of the system. Pressure on healthcare budgets is a structural reality. Given limited public resources, qualified advocacy participates in designing innovative financing models such as pay-for-performance agreements (risk-sharing), which seek to reconcile the incorporation of disruptive technologies with the financial stability and long-term viability of healthcare systems.

Looking toward rare diseases must become a call for collective action. The reality is not homogeneous: while some countries have consolidated specific regulatory frameworks, such as the Orphan Drug Act in the United States or strategic plans in various European countries, others still face structural challenges ranging from expanding newborn screening to building robust registries.

The potential to lead in genetics and precision medicine exists in multiple regions of the world. However, that leadership will only be sustainable if ecosystems capable of effectively integrating science, public policy, and strategic communication are developed.

Giving voice to people living with a rare disease is not an act of charity: it is a public health obligation and a commitment to human rights. Every time a country incorporates a therapy for a rare disease, it not only expands access; it strengthens the transparency, equity, and humanity of its healthcare system as a whole.

We reaffirm that the rare can no longer remain invisible. How we respond to rare diseases ultimately defines the quality and equity of health systems.